Provided By GlobeNewswire
Last update: Jan 6, 2025
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company.
Read more at globenewswire.comNASDAQ:RAPT (9/5/2025, 4:30:01 PM)
12.93
+0.2 (+1.57%)
Find more stocks in the Stock Screener